The company is divesting its Exosome Diagnostics business to improve profitability. This corporate action will create operational and IT complexity related to separating systems, migrating data, and establishing new workflows for the remaining business segments.
Filing excerpt
gross margin for the quarter and six months ended December 31, 2025 was favorably impacted by the Exosome Diagnostics divestiture and ongoing profitability initiatives...
What this signalsFilings often name leadership changes, deals and spending plans.
sec-10qdivestitureGet every 10-Q signal for Bio-Techne and the companies you sell to, in the tools you already use.
Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Bio-Techne this week?”
The Signal API returns 10-Q signals for any list of companies as JSON, for your CRM, warehouse or app.
Sign up and spend your free credits on the companies you sell to.
This page shows a preview. The full sec-10q record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.
Company
linkedin_urlValue in the APIindustriesValue in the APIemployee_count_lowValue in the APIemployee_count_highValue in the APIrevenueValue in the APIdescriptionValue in the APISignal
signal_nameValue in the APIassociationValue in the APIGET /v1/signals/358d9de5-663f-4a96-93ca-1c1f496c0eaf returns this record as JSON. POST /v1/companies/enrich returns every signal for bio-techne.com.
{
"signal_id": "358d9de5-663f-4a96-93ca-1c1f496c0eaf",
"signal_type": "sec-10q",
"signal_subtype": "divestiture",
"detected_at": "2026-02-10T08:25:18.163+00:00",
"company": {
"name": "Bio-Techne",
"domain": "bio-techne.com"
},
"data": {
"detail": "The company is divesting its Exosome Diagnostics business to improve profitability. This corporate action will create operational and IT complexity related to separating systems, migrating data, and establishing new workflows for the remaining business segments.",
"metrics": {
"timeframe": "current_year",
"dollar_context": "Cash received for assets held-for-sale during the six months ended December 31, 2025",
"dollar_millions": 4.6
},
"summary": "Bio-Techne divesting Exosome Diagnostics business as part of profitability initiative",
"excerpts": "gross margin for the quarter and six months ended December 31, 2025 was favorably impacted by the Exosome Diagnostics divestiture and ongoing profitability initiatives...",
"relevance": 0.85,
"sentiment": "positive",
"confidence": "high",
"source_url": "https://www.sec.gov/Archives/edgar/data/842023/000110465926010335/tech-20251231x10q.htm",
"filing_date": "2026-02-04",
"filing_year": 2026,
"fiscal_year": 0,
"sales_relevance": "Carve-out support needed",
"signal_category": "strategic"
}
}
curl https://signals.autobound.ai/v1/signals/358d9de5-663f-4a96-93ca-1c1f496c0eaf \
-H "X-API-KEY: $AUTOBOUND_API_KEY"curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"bio-techne.com","limit":20}'Long text fields are shortened on this page.
Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.